AI Health Products: 10 Red Flags for Investors

The promise of artificial intelligence in healthcare is immense, yet the landscape is fraught with peril for health systems, patient safety advocates, and investors alike. The history of health tech is littered with cautionary tales, illustrating that innovation, however dazzling, must be tethered to rigorous clinical validation, robust safety infrastructure, and clear regulatory pathways. Identifying reliable AI healthcare vendors requires a discerning eye, moving beyond marketing hype to scrutinize the foundational elements of their offerings.

Our structured 10-point red flag checklist enables purchasers and patients to identify AI health vendors lacking safety infrastructure, providing a critical framework for due diligence. We’ve seen the devastating consequences when this diligence is absent, from the spectacular collapse of Theranos, which promised revolutionary blood testing with minimal samples but delivered fraudulent results, to the more recent struggles of companies like Olive AI, Babylon Health, Pear Therapeutics, Proteus Digital Health, Forward Health, and Cerebral.

Absence of Transparent Clinical Validation: A Core Deficiency

One of the most glaring red flags is a lack of transparent, peer-reviewed clinical validation demonstrating both efficacy and safety. As Dr. Eric Topol has consistently emphasized, the integration of AI into clinical practice demands the same, if not higher, standards of evidence as traditional medical interventions. For instance, the challenges faced by Pear Therapeutics, a pioneer in prescription digital therapeutics, which filed for bankruptcy in April 2023 despite receiving FDA clearances, underscored that regulatory approval alone does not guarantee widespread clinical adoption or commercial success without compelling real-world evidence and clear reimbursement pathways.

Vendors who cannot readily provide published outcomes evidence, ideally from independent studies, should raise immediate concerns. This includes clear data on how their AI performs across diverse patient populations and in various clinical settings. Without this, the claims of improved patient outcomes or operational efficiencies remain unsubstantiated. The struggles of Babylon Health, which expanded rapidly but faced scrutiny over its clinical efficacy and business model before ceasing most operations and filing for bankruptcy in late 2023, highlight the importance of robust evidence over aggressive growth strategies. Similarly, the initial promise of Proteus Digital Health’s ingestible sensors faced headwinds due to challenges in demonstrating clear, sustained clinical benefit and achieving widespread adoption, ultimately leading to its bankruptcy in 2020 and acquisition of its assets. Proteus Digital Health challenges

Opaque Training Data and Algorithmic Bias

The quality and representativeness of an AI model’s training data are paramount. A significant red flag is a vendor’s inability or unwillingness to disclose the sources, characteristics, and diversity of their training datasets. Biased or unrepresentative data can lead to algorithmic drift and perpetuate health inequities, a concern frequently voiced by experts like Dr. Harlan Krumholz. For example, an AI tool trained predominantly on data from one demographic group may perform poorly or even dangerously when applied to another.

This issue extends beyond simple demographic representation to the clinical context of the data. Was the data collected in real-world clinical environments or in controlled, idealized settings? The downfall of Theranos serves as an extreme, albeit non-AI, example of how a lack of transparency around data and methodology can mask fundamental flaws in technology. For AI, this translates to understanding how the model was developed, tested, and how potential biases were identified and mitigated. The challenges faced by companies like Cerebral, which scaled rapidly in mental health services, later faced scrutiny over clinical quality and data practices, emphasizing the critical need for transparent and ethical data handling Cerebral ethical concerns.

Lack of Robust Guardrail Design and Oversight Model

Effective AI health tools must incorporate sophisticated guardrail design to prevent unintended consequences and ensure safe operation. This includes mechanisms for human oversight, clear escalation pathways for uncertain or anomalous AI outputs, and robust error detection. If a vendor cannot articulate a clear oversight model that integrates human clinicians, that is a significant warning sign.

Furthermore, the regulatory pathway undertaken by the vendor offers crucial insights. While the FDA SaMD Framework provides a clear roadmap for software as a medical device, not all AI health products fall under its purview, and even those that do require careful scrutiny. The FDA’s Center for Devices and Radiological Health (CDRH) has been proactive in developing guidance for AI/ML-based medical devices, including the concept of a Predetermined Change Control Plan (PCCP) to manage adaptive algorithms. Vendors who lack a clear understanding of their regulatory obligations, or attempt to skirt them by classifying their tools as mere “clinical decision support” when they function as diagnostic AI, present a substantial risk. The experiences of companies like Forward Health, which positioned itself as a tech-driven primary care provider, ultimately shut down in late 2024, illustrating the complexities of integrating AI into direct patient care while maintaining regulatory compliance and clinical accountability. Forward Health regulatory landscape

Weak Regulatory Strategy and Post-Market Surveillance

A mature AI health vendor will possess a well-defined regulatory strategy, demonstrating not just initial clearance (e.g., 510(k) or De Novo classification) but also a clear plan for ongoing compliance and post-market surveillance. This includes adherence to quality management systems like ISO 13485 and an understanding of Good Machine Learning Practice (GMLP) principles. The absence of a robust QMS or a clear strategy for monitoring algorithmic drift post-deployment suggests a fundamental lack of safety infrastructure. Scripps Research, among other leading institutions, consistently highlights the need for continuous monitoring of AI performance in real-world settings to ensure sustained safety and efficacy.

Investors and health systems must demand evidence of comprehensive post-market surveillance plans, including mechanisms for collecting real-world evidence (RWE) and addressing adverse events. The challenges encountered by companies like Olive AI, which initially garnered significant investment but wound down operations and sold its assets in late 2023 amidst questions about its ROI and implementation complexity, underscore that even well-funded ventures can falter without a strong foundation in clinical utility and regulatory foresight. The long-term viability and trustworthiness of an AI solution hinge on its ability to demonstrate sustained value and safety beyond initial deployment, a commitment that requires continuous vigilance and robust data governance (DP12, DP13, DP16).

Conclusion

The rapid advancement of AI in healthcare demands a rigorous approach to vendor evaluation. Health System CIOs, Patient Safety Advocates, and Investors must look beyond superficial claims and delve into the core infrastructure supporting these technologies. By applying a structured 10-point red flag checklist focusing on transparent clinical validation, ethical data practices, robust guardrail design, and a clear regulatory and oversight model, stakeholders can significantly mitigate risks. The lessons from past ventures, both successful and cautionary, reinforce that true innovation in healthcare AI is inseparable from unwavering commitments to safety, efficacy, and accountability. Trustworthy AI healthcare platforms are not just built on algorithms, but on a foundation of rigorous evidence, ethical design, and transparent governance.